Working… Menu

Cell-mediated Immunity for Prevention of CMV Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02538172
Recruitment Status : Completed
First Posted : September 2, 2015
Last Update Posted : April 28, 2021
Information provided by (Responsible Party):
Oriol Manuel, University of Lausanne Hospitals

Brief Summary:

An open-label randomized controlled trial to adapt the duration of antiviral prophylaxis in D+/R- patients and in R+ patients receiving ATG according to the result of the T-Track® CMV assay. Investigators will include kidney and liver transplant recipients. Patients will be randomized during the first month post transplant.

In the interventional arm, while the patient is on antiviral prophylaxis, CMI will be monitored every 4 weeks from the 2nd month after transplant. Measurement of CMV CMI will be done in real time by using the T-Track® CMV assay. The continuation of antiviral prophylaxis will depend on the result of the assay:

  • T-Track positive (patient at lower risk): discontinuation of the antiviral drug
  • T-Track negative (patient at higher risk): continuation of the antiviral drug until the maximal duration of prophylaxis (3 to 6 months) The standard arm will receive a standard fixed duration of antiviral prophylaxis (3 months for R+ thymoglobulin treated-patients and 6 months for D+/R- patients). Measurement of CMV CMI by both T-Track® CMV and the Quantiferon-CMV® assays will be done at the same time points of the interventional arm, but the result will not be known by the investigators.

After discontinuation of prophylaxis, patients in both arms will be followed for the development of CMV replication at each visit using the local PCR assay and antiviral therapy will be administered in case of CMV infection according to local guidelines.

The co-primary endpoints will be the incidence of CMV disease or antiviral-treated CMV replication during the first 12 months post transplant AND the duration of antiviral prophylaxis.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Infections Other: T-Track® CMV assay Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Monitoring of Specific Cytomegalovirus Cell-mediated Immunity (CMV-CMI) for Optimization of Preventive Strategies Against CMV Infection in High-risk Solid-organ Transplant Recipients
Study Start Date : October 2015
Actual Primary Completion Date : December 2019
Actual Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intervention
T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
Other: T-Track® CMV assay
Other Names:
  • Quantiferon-CMV® assays
  • Valganciclovir

T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
Other: T-Track® CMV assay
Other Names:
  • Quantiferon-CMV® assays
  • Valganciclovir

Primary Outcome Measures :
  1. Incidence of CMV infection [ Time Frame: one year ]
  2. Duration of antiviral prophylaxis [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Graft survival [ Time Frame: one year ]
  2. Incidence of CMV viremia using standardized measure [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years old
  • Kidney or liver transplantation
  • Scheduled to receive CMV antiviral prophylaxis:
  • CMV D+/R- patients
  • Patients receiving lymphocyte-depleting antibodies (thymoglobulin® or ATG®)

Exclusion Criteria:

  • Unable to provide informed consent
  • Unable or unwilling to comply with study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02538172

Layout table for location information
Universität Basel
Basel, Switzerland, 4051
Universitätsspital Bern
Bern, Switzerland, 3010
Hopitaux Universitaires de Genève
Genève, Switzerland, 1205
Kantonsspital St.Gallen
St. Gallen, Switzerland, 9007
UniversitätsSpital Zürich
Zürich, Switzerland, 8091
Sponsors and Collaborators
University of Lausanne Hospitals
Layout table for investigator information
Principal Investigator: Oriol Manuel, MD University of Lausanne Hospitals
Publications of Results:
Layout table for additonal information
Responsible Party: Oriol Manuel, Privat-Docent (PD), University of Lausanne Hospitals Identifier: NCT02538172    
Other Study ID Numbers: STCS FUP # 052
First Posted: September 2, 2015    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: April 2021
Keywords provided by Oriol Manuel, University of Lausanne Hospitals:
Cell-mediated immunity
Antiviral prophylaxis
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Antiviral Agents
Anti-Infective Agents